Severe Anemia Due to Parvovirus Infection Following Treatment with Rituximab in a Pediatric Kidney Transplant Recipient: Anemia after Treatment of Rituximab in Kidney Recipient Patient
Childhood Kidney Diseases
; : 176-179, 2015.
Article
in En
| WPRIM
| ID: wpr-43529
Responsible library:
WPRO
ABSTRACT
Rituximab (RTX), a monoclonal antibody against the B-cell marker CD20, is commonly used as a treatment for antibody-mediated diseases or B-lymphocyte-mediated diseases. Destruction of B cells may reverse the disease course in many conditions; however, patients who are treated with RTX cannot respond appropriately to de novo infection due to lack of B lymphocytes. Here, we report one such case. A 7-year-old renal allograft recipient presented with severe anemia due to parvovirus infection after RTX treatment. The patient had focal segmental glomerulosclerosis and had received cadaveric kidney transplantation 6 months previously. She was treated with high-dose steroid for acute rejection and RTX for Epstein Barr Virus infection 3 months previously. At presentation, her hemoglobin level was 5.4 g/dL and leukocyte and platelet counts were normal. She had microcytic normochromic anemia and high viral load of parvovirus B19(70,578 copies/mL). Intravenous immunoglobulin (200 mg/kg.d) treatment controlled the progression of anemia and parvovirus infection. De novo parvovirus infection during the B lymphocyte-depletion period may have precipitated the severe anemia in this case. Close monitoring of infection is required after RTX therapy.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Platelet Count
/
Transplantation
/
Cadaver
/
Immunoglobulins
/
B-Lymphocytes
/
Glomerulosclerosis, Focal Segmental
/
Kidney Transplantation
/
Parvovirus
/
Herpesvirus 4, Human
/
Parvoviridae Infections
Limits:
Child
/
Humans
Language:
En
Journal:
Childhood Kidney Diseases
Year:
2015
Type:
Article